Sotac Pharmaceuticals Limited (NSE:SOTAC)
India · Delayed Price · Currency is INR 90.05
0.00 (0.00%)
Oct 1, 2026, 2:34 PM IST
Sotac Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,012 | 997.37 | 1,038 | 774.83 | 731.52 |
Other Revenue | 0.18 | 1.92 | 0.5 | - | - |
| 1,013 | 999.29 | 1,039 | 774.83 | 731.52 | |
Revenue Growth | 1.33% | -3.80% | 34.07% | 5.92% | 49.77% |
Cost of Revenue | 646.99 | 685.07 | 796.12 | 572.69 | 559.77 |
Gross Profit | 365.58 | 314.22 | 242.69 | 202.14 | 171.75 |
Selling, General & Admin | 37.16 | 32.1 | 40.36 | 42.93 | 30.04 |
Other Operating Expenses | 148.02 | 112.45 | 114.12 | 83.31 | 61.93 |
Operating Expenses | 239.23 | 182.89 | 185.48 | 149.01 | 103.24 |
Operating Income | 126.35 | 131.33 | 57.2 | 53.13 | 68.51 |
Interest Expense | -40.14 | -22.41 | -15.51 | -19.02 | -5.02 |
Interest & Investment Income | 1.19 | 1.65 | 1.82 | 0.46 | 0.48 |
Currency Exchange Gain (Loss) | - | - | -0.07 | - | - |
Other Non Operating Income (Expenses) | -1.26 | -3.48 | -1.81 | -1.11 | 1.33 |
EBT Excluding Unusual Items | 86.13 | 107.09 | 41.63 | 33.47 | 65.31 |
Gain (Loss) on Sale of Investments | - | - | - | - | -18.36 |
Gain (Loss) on Sale of Assets | 0.86 | 4.11 | - | - | - |
Other Unusual Items | -0.02 | -0 | -2.34 | 5.8 | - |
Pretax Income | 86.96 | 111.2 | 39.64 | 39.27 | 46.95 |
Income Tax Expense | 24.03 | 18.44 | 3.85 | 16.41 | 18.16 |
Earnings From Continuing Operations | 62.93 | 92.75 | 35.79 | 22.86 | 28.79 |
Minority Interest in Earnings | -5.27 | -12.49 | 7.02 | 5.93 | - |
Net Income | 57.67 | 80.27 | 42.81 | 28.79 | 28.79 |
Net Income to Common | 57.67 | 80.27 | 42.81 | 28.79 | 28.79 |
Net Income Growth | -28.16% | 87.48% | 48.69% | 0.02% | - |
Shares Outstanding (Basic) | 11 | 11 | 11 | 8 | 8 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 8 | 8 |
Shares Change | - | 0.67% | 36.35% | - | - |
EPS (Basic) | 5.22 | 7.26 | 3.90 | 3.58 | 3.58 |
EPS (Diluted) | 5.22 | 7.26 | 3.90 | 3.58 | 3.58 |
EPS Growth | -28.12% | 86.15% | 9.04% | 0.02% | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 89.59 | -213.66 | -338.65 | -8.57 | 28.46 |
Free Cash Flow Per Share | 8.11 | -19.34 | -30.85 | -1.06 | 3.54 |
Dividend Per Share | 0.200 | 0.100 | - | - | 2.000 |
Dividend Growth | 100.00% | - | - | - | - |
Gross Margin | 36.10% | 31.44% | 23.36% | 26.09% | 23.48% |
Operating Margin | 12.48% | 13.14% | 5.51% | 6.86% | 9.37% |
Profit Margin | 5.70% | 8.03% | 4.12% | 3.72% | 3.94% |
Free Cash Flow Margin | 8.85% | -21.38% | -32.60% | -1.11% | 3.89% |
EBITDA | 180.32 | 169.63 | 88.16 | 75.89 | 79.77 |
EBITDA Margin | 17.81% | 16.98% | 8.49% | 9.79% | 10.90% |
D&A For EBITDA | 53.98 | 38.3 | 30.95 | 22.76 | 11.26 |
EBIT | 126.35 | 131.33 | 57.2 | 53.13 | 68.51 |
EBIT Margin | 12.48% | 13.14% | 5.51% | 6.86% | 9.37% |
Effective Tax Rate | 27.63% | 16.59% | 9.70% | 41.78% | 38.68% |
Revenue as Reported | 1,016 | 1,009 | 1,043 | 778.33 | 733.7 |
Advertising Expenses | - | - | 0.05 | 0.3 | 0.02 |